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Acenocoumarol is an oral anticoagulant with significant interindividual dose variations. Variants 
in CYP2C9 and VKORC1 have been associated with acenocoumarol maintenance dose. We 
analysed whether any of the 49 polymorphisms in CYP2C9 and VKORC1 previously associated with 
acenocoumarol maintenance dose in a Genome-Wide Association study (GWAs) in Dutch population are 
associated with stroke recurrence, intracranial haemorrhage (icH) and acenocoumarol maintenance 
dose in a Spanish population. We performed a GWAs using Human Core Exome-chip (Illumina) in 78 
patients stroke patients treated with acenocoumarol for secondary prevention enrolled as part of the 
prospective investigator-initiated study (IIS) SEDMAN Study. Patients were followed-up a median 
of 12.8 months. Three and eight patients had recurrent stroke and ICH events, respectively. We 
found 14 of the 49 published variants associated with acenocoumarol maintenance dose (p < 0.05). 
Six polymorphisms were associated with stroke recurrence and four variants with ICH (p < 0.05). In 
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conclusion, variants in VKORC1 and CYP2C9 are associated with acenocoumarol maintenance dose, 
stroke recurrence and ICH in a Spanish cohort. These results highlight the relevance of studying 
pharmacogenetics associated with efficacy and safety of anticoagulant drugs and justify studies with 
larger sample size and different ethnic populations.
Oral anticoagulants (OAs) are used for the treatment and prevention of thromboembolic diseases. Vitamin K 
antagonists (VKAs) are the most frequently prescribed OAs1, warfarin being the most used VKA worldwide. 
In Europe, fluindione, which is mostly prescribed in France2, or acenocoumarol and phenprocoumon, widely 
used in continental European countries2 are highly prescribed. They have similar properties to warfarin but a 
different half-life2,3. Direct-acting OAs (DOACs) are OAs with different targets to VKAs: rivaroxaban, edoxaban, 
and apixaban inhibit Xa factor, while dabigatran inhibits thrombin directly4. Given the different targets for OAs, 
personalized medicine (PM) could help in choosing the safest and most effective OA for each patient.
Despite being very effective, acenocoumarol has a narrow therapeutic window, high inter-individual var-
iability in its pharmacokinetics and a number of drug interactions that increase the risk of new or recurrent 
vascular events and bleeding complications5. Age, sex, height, body weight, and concomitant treatments are the 
most relevant clinical factors associated with inter-individual acenocoumarol variation. Genetic factors are also 
important, mainly polymorphisms in the VKORC1 and CYP2C9 genes5, which are involved in acenocouma-
rol metabolism. Variants in or near these genes are associated with acenocoumarol maintenance dose, the first 
International Normalized Ratio (INR) result after standard dose, the time to stable dose, time in therapeutic 
range, and bleeding events6. Only one Genome-Wide association study (GWAs) investigating the association with 
variance of acenocoumarol maintenance dose has been performed6. They found association of 53 SNPs, most of 
them replicated in a second cohort, located in or near the VKORC1 and CYP2C9 genes6.
The frequency and effect of genetic variants is different among populations. It is important to evaluate the role 
of genetic variants in each specific community before clinical application. Variants on VKORC1 and CYP2C9 have 
been studied in different populations such as Russia, Chile, Serbia, and Spain, among others5,7–9. In Spain, some 
of these variants were found to be associated with time in therapeutic range, dose requirements, INR values, and 
risk of bleeding events in candidate gene studies1,10,11. However, as far as we know, no study has evaluated the role 
of these polymorphisms in stroke recurrence.
The objective of the present study is to evaluate whether the polymorphisms associated with acenocoumarol 
maintenance dose from the published GWAs6 are associated with stroke recurrence in a Spanish population, 
which has not been studied previously. Furthermore, we intend to confirm whether these variants are also asso-
ciated with acenocoumarol maintenance dose and intracranial haemorrhage (ICH) occurrence. These results 
could address the question of whether using the right treatment for the right patient could be implemented in the 
Spanish population.
Results
Sample size calculation based on the acenocoumarol GWAs6 showed that a minimum of 68 patients offer enough 
power for replication (p < 0.001) of polymorphisms associated with acenocoumarol maintenance dose. We eval-
uated 78 patients (44.9% men) with a median age of 79 years who were treated with acenocoumarol at a mean 
weekly maintenance dose of 12.25 mg/week. Patients were followed up for a median of 12.8 months. The median 
NIHSS at baseline and at discharge was 4.5 and 1, respectively (Table 1).
From the 49 polymorphisms analysed, 14 SNPs were associated with acenocoumarol maintenance dose with 
p-values of <0.05 (Fig. 1). Four of these polymorphisms (rs1978487, rs4889490, rs749767, and rs889548) were 
also statistically significant when Bonferroni correction was applied. The polymorphisms rs1978487, rs749767, 
and rs889548 were among the top four more significant SNPs in the discovery analysis from the published 
GWAs6, with p-values of 7.82 × 10−104, 3.08 × 10−103, and 5.61 × 10−106, respectively (Table 2).
We also evaluated the association of the 49 published polymorphisms with stroke recurrence and with ICH 
events during follow-up. Three (3.8%) and eight (10.2%) patients had a recurrent IS or ICH, respectively (Table 1). 
Six out of the 49 polymorphisms (rs8046001, rs4086116, rs4917639, and rs11150596) were associated with stroke 
recurrence. Two (rs8046001 and rs11150596) of these polymorphisms were also associated with acenocoumarol 
maintenance dose in our cohort (Table 2), showing association for two traits at the same time. Four variants 
were associated with ICH (rs4889490, rs889548, rs10871454, and rs7197475). Three of these variants (rs4889490, 
rs889548, and rs10871454) were associated with acenocoumarol maintenance dose in our analysis (Table 2). 
Moreover, the combined analysis of recurrent strokes and ICH events showed eight polymorphisms significantly 
associated with this outcome (Table S1). Polygenic risk scores considering the independent polymorphisms from 
the published GWAs for acenocoumarol maintenance dose6 showed an association with IS recurrence (p = 0.001) 
but not for ICH events nor acenocoumarol maintenance dose (p = 0.691 and 0.086, respectively).
Survival curves showed significant differences (p < 0.05) in the incidence of stroke recurrence and ICH events 
over time depending on rs741810 and rs10871454 genotypes, respectively. For the other polymorphisms the dif-
ferences were not significant, despite some trends that could be observed in plots (Figs. S2 and S3).
Discussion
We studied a Spanish cohort, analysing the polymorphisms previously associated with acenocoumarol mainte-
nance dose in a previous GWAs in patients from the Netherlands6. The polymorphisms were located in or near 
the VKORC1 and CYP2C9 genes. Population-specific genetic properties make it necessary to perform GWAs for 
each population to confirm its implication for the disease.
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Variations in VKORC1 and CYP2C9 have previously been associated with different parameters related to 
acenocoumarol1, but their implication for recurrence of IS has not been consistently elucidated and the results 
have been controversial. One analysis compared the use of algorithms for VKAs initial-dose guiding versus clas-
sical dosing. They did not find any effect of using genetic algorithms on a reduction in the risk of thromboem-
bolic events12. However, one candidate-gene study found that variants in VKORC1 and CYP2C9 were associated 
with thrombotic events, such as stroke, TIA, and venous thromboembolism, among others13. Furthermore, two 
studies that included patients from the Chinese Han population found that VKORC1 mutations were associ-
ated with a higher risk of cardiovascular diseases, including stroke14,15. Since polymorphisms in these genes are 
associated with less sensitivity to VKAs, patients with these variants and without a good dosage are at high risk 
of suffering another stroke or systemic embolism14. In our study, we saw that several of the variants associated 
with acenocoumarol maintenance dose in our cohort are also associated with the risk of suffering another stroke. 
Furthermore, some of the variants associated with acenocoumarol dose in the previous GWAs, are associated 
with recurrent stroke in our population, despite not being associated with acenocoumarol maintenance dose in 
our study. Moreover, the polygenic risk score based on the results from the previous GWAs highlight the impor-
tance that polymorphisms previously associated with acenocoumarol maintenance dose have also for the risk of 
recurrent stroke. Moreover, the lack of association (although a trend is observed) of the score with acenocoumarol 
maintenance dose could be related with the differences existing between populations.
Furthermore, we found polymorphisms associated with maintenance dose that are also associated with ICH 
events. These results show that these polymorphisms should be taken into account for acenocoumarol dos-
ing because of their implication for the efficacy and safety of the treatment. However, the polygenic risk score 
obtained from previous GWAs did not show association with ICH events. One possible explanation is the lack 
of association previously documented16 for polymorphisms in CYP2C9 and ICH. Another reason could be the 
different population where these variants have been studied.
Different pharmacogenetic algorithms have been developed in different populations, including the most com-
mon polymorphisms in VKORC1 and CYP2C9 to be used in clinical practice1,5,17–21. However, they do not explain 
all drug variability. Some of the variants found by a GWAs approach could be in these pharmacogenetic algo-
rithms included in the future. However, it is important to find the association of genetic variants in each specific 
population before using genetic algorithms to ensure its plausibility in clinical practice. In this case, variants asso-
ciated in a previous GWAs replicated in our Spanish cohort could be applied to the current algorithms to develop 
a specific algorithm designed for Spanish patients. These algorithms should focus on stroke recurrence and ICH 
events, two important variables from a clinical point of view. The fact that these SNPs are associated with vascular 
recurrence in the Spanish population could allow PM to establish the correct dose and choose an OA for which 
these polymorphisms are not relevant, such as dabigatran or other DOACs22.
N 78
Sex
Men, n (%) 35 (44.9%)
Women, n (%) 43 (55.1%)
Median age, years (25–75%) 79 (70–83)
Mean dose, mg/week (SD) 12.25 (5.9)
Median follow-up, months (25–75%) 12.8 (10.64–16.79)
Median NIHSS at baseline (25–75%) 4.5 (2–7.75)
Median NIHSS at 24 hr. (25–75%) 1.5 (0–5)
Median NIHSS at discharge (25–75%) 1 (0–2)
Median CHA2DS2-VASc score (25–75%) 4 (2–5)
Median HAS-BLED score (25–75%) 2 (1–2)
HTN, n (%) 53 (67.9%)
DM, n (%) 17 (21.8%)
Smoking, n (%) 13 (16.7%)
Stroke recurrence, n 3 (3.8%)
Median time to stroke recurrence, months 
(25–75%) 9.79 (4.17–10.74)
ICH, n (%) 8 (10,2%)
Median time to ICH, months (25–75%) 3.94 (2.73–5.22)
Acenocoumarol discontinuation 13 (17.3%)
Causes:
Labile INR, n (%) 7 (9.3%)
Stroke recurrence/bleeding event, n (%) 1 (1.3%)
Other*, n (%) 5 (6.6%)
Table 1. Demographic description of the cohort. Description of the main characteristics of the cohort included 
in this analysis. NIHSS: National institute of Health Stroke Scale; HTN: Hypertension; DM: Diabetes Mellitus; 
ICH: Intracranial haemorrhage; INR: International normalized ratio; 25–75%: percentile 25% and percentile 
75%; SD: Standard deviation. *Other reasons for discontinuation: cancer, fractures, and unspecified reasons.
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Our study has some clear limitations. Mainly, the sample size is too small to find new polymorphisms associ-
ated with acenocoumarol maintenance dose in our cohort, but we calculated that it is enough to replicate some 
of the main candidate polymorphisms. With this sample size we have been able to detect variants in or near 
VKORC1 and CYP2C9 associated with acenocoumarol dose, stroke recurrence, and ICH in a Spanish cohort.
Methods
Patients were included as part of the ongoing SEDMAN study (‘Dabigatran study in the early phase of stroke. New 
neuroimaging markers and biomarkers study’), with ClinicalTrials.gov number: NCT02742480. The SEDMAN 
study is a prospective, multicentre, investigator-initiated study (IIS) that consecutively enrolled stroke patients 
from 12 different Spanish sites from June 2016 to January 2019 (the Supplementary Material includes the detailed 
methodology of the study). For the present analysis, patients from the SEDMAN study who met the follow-
ing inclusion criteria were analysed: cardioembolic stroke patients who initiated acenocoumarol treatment after 
stroke who had completed a minimum of 6 months’ follow-up. All patients or their legal representatives signed 
the informed consent and the project was approved by the Mútua de Terrassa Ethics Committee and then for 
every participating hospital. All methods were performed in accordance with the relevant guidelines and regula-
tions for studies with human samples.
Study endpoints. The primary endpoint of the study was the recurrence of symptomatic ischemic stroke 
(IS). IS diagnostic was based on neurologist criteria following physical examination and neuroimaging (com-
puted tomography, CT or magnetic resonance imaging, MRI) in patients during treatment with acenocoumarol. 
We excluded patients with transient ischemic attack (TIA). We considered as IS all neurological dysfunctions 
produced by focal infarction observed by neuroimaging techniques and classified as cardioembolic, lacunar ath-
erothrombotic and undetermined within the TOAST classification.
The secondary endpoints analysed were: (1) Acenocoumarol maintenance dose (considered when 3 or more 
INR measures ranged between 2 and 3 for 3 weeks or more21), and (2) Any symptomatic or asymptomatic spon-
taneous ICH events. Non-traumatic ICH was diagnosed when bleeding in the parenchyma (intraparenchymal 
haemorrhage) or the ventricular system (intraventricular haemorrhage) of patients was observed through neuro-
imaging techniques (CT or MRI). We excluded traumatic ICHs and (3) Combination of ICH events and recurrent 
strokes”.
Figure 1. Mean dose requirements. Boxplot representing mean dose of acenocoumarol in mg/week (Y-axis) 
according to the genotype (X-axis) for (A) rs4889490, (B) rs749767, (C) rs1978487, and (D) rs889548.
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Follow-up. Patients were followed up using their clinical records or through telephone and clinical visits by 
an experienced neurologist. For the present interim analysis, a minimum of 6 months’ follow-up was considered 
for the recurrence and ICH registry.
Genome-wide association study, and selection of polymorphisms. A total of 164 patients were 
genotyped using the Human Core Exome chip (Illumina) at Washington University (St. Louis). We performed 
quality controls following previous recommendations for samples and polymorphisms23 and we imputed the 
genetic variants with the Michigan Imputation Server24, using genotypes from 1000-Genomes Project.
From the genotyped patients, we selected 85 patients who met the inclusion criteria for this specific analysis. 
After quality controls, we analysed 78 patients. From all the polymorphisms imputed, we selected those associated 
with acenocoumarol maintenance dose in the only GWAs published in this field analysing acenocoumarol main-
tenance dose in Dutch population6. A total of 49 SNPs with significant p-values in the discovery (p < 5 × 10−8) 
and replication (p < 0.05) analyses were selected for our study (Table 2).
We have focused only on GWAs results because candidate gene studies are biased and in the case of acenocou-
marol pharmacogenetics, those genes and SNPs have not been replicated or validated consistently. In contrast, 
GWAs are unbiased techniques with higher sample sizes and replication stages that are more effective in finding 
SNPs associated with a condition or disease.
Statistical analysis. For the association analysis of polymorphisms and the different endpoints, SNPTEST 
v2.5.4-beta3 software was used25. We used the method “expected” to control genotype uncertainty. We included 
sex, age, and principal components 1 and 2 as covariates in the different analyses.
We calculated the sample size needed with the pwr package26 in R using “pwr.2p.test: two-sample proportion 
test” (for univariate analyses) and “pwr.f2.test: test for the general linear model” (for multivariate analyses). For 
the analysis of acenocoumarol maintenance dose, we considered beta values from the published GWAs6 and a sta-
tistical power of 0.8. For the sample size calculation needed in the pharmacogenetic analyses of stroke recurrence 
and ICH, we considered the number of ICH events associated with VKORC1 genotype from Jiménez-Varo et al.1 
and the total number of bleeding events associated with CYP2C9 obtained from Visser et al.27. In the absence of 
articles investigating the association of these specific polymorphisms with the risk of recurrent stroke in patients 
treated with acenocoumarol, we assumed the mentioned calculation for ICH events as valid for stroke recurrence 
analysis. Using the two-sample proportion test we obtained that the minimum sample size needed to identify 
associations was 50 while using the test for the general linear model we obtained that the sample size needed was 
81 patients.
SNP BP CHR effect locus p-liter beta-liter beta-dose p-dose beta-stroke p-stroke beta-ICH p-ICH beta-comb p-comb
rs8046001 30833321 16 VKORC1 7.40 × 10−33 2.823 0,61 0,009 3.021 0,009 1.083 0,12 1.929 0,002
rs11150596 30850242 16 VKORC1 1.81 × 10−35 2.936 0,61 0,009 3.021 0,009 1.083 0,12 1.929 0,002
rs10871454 31048079 16 VKORC1 2.00 × 10−123 −5.162 −0,67 0,007 −0,931 0,39 −2.015 0,02 −1.668 0,01
rs9933843 30903679 16 VKORC1 2.58 × 10−47 3.325 −0,556 0,01 −2.486 0,06 −1.033 0,17 −1.820 0,01
rs8058961 30809063 16 VKORC1 9.03 × 10−14 1.956 −0,323 0,24 −2.204 0,05 −1.266 0,13 −1.639 0,01
rs889548 31137712 16 VKORC1 5.61 × 10−106 −4.867 −0,807 0,001 −0,944 0,39 −1.802 0,03 −1.601 0,02
rs7197475 30642867 16 VKORC1 9.32 × 10−20 2.147 0,152 0,54 1.151 0,3 1.703 0,02 1.473 0,02
rs4889630 30877544 16 VKORC1 1.98 × 10−10 1.837 0,297 0,32 2.296 0,13 1.220 0,18 1.436 0,05
rs3747481 30666367 16 VKORC1 1.42 × 10−11 1.804 0,294 0,32 2.201 0,05 0,735 0,38 1.303 0,05
rs8058578 30726248 16 VKORC1 3.93 × 10−12 1.846 0,294 0,32 2.201 0,05 0,735 0,38 1.303 0,05
rs1978487 31129942 16 VKORC1 7.82 × 10−104 −4.827 0,855 8,0 × 10−04 0,981 0,37 1.373 0,1 1.264 0,06
rs749767 31124407 16 VKORC1 3.08 × 10−103 −4.818 −0,813 0,001 −0,954 0,39 −1.065 0,18 −1.128 0,09
rs741810 31193942 16 VKORC1 4.68 × 10−19 2.163 −0,065 0,8 −13,63 0,005 0,124 0,89 −0,912 0,21
rs8056505 31214898 16 VKORC1 2.49 × 10−19 2.178 −0,0654 0,8 −13,63 0,005 0,1239 0,89 −0,912 0,21
rs4086116 96707202 10 CYP2C9 3.29 × 10−24 −2.879 −0,311 0,26 −11.040 0,04 −0,078 0,92 −0,756 0,29
rs4917639 96725535 10 CYP2C9 8.02 × 10−24 −2.866 −0,311 0,26 −11.040 0,04 −0,078 0,92 −0,756 0,29
rs11642466 30781942 16 VKORC1 5.60 × 10−14 2.767 0,828 0,01 1.411 0,24 −0,269 0,81 0,901 0,3
rs9332169 96731310 10 CYP2C9 8.34 × 10−12 −3.442 −0,72 0,03 −11.270 0,09 −0,198 0,84 −1.021 0,31
rs10509680 96734339 10 CYP2C9 8.34 × 10−12 −3.442 −0,72 0,03 −11.270 0,09 −0,198 0,84 −1.021 0,31
rs1057910 96741053 10 CYP2C9*3 6.44 × 10−12 −3.459 −0,72 0,03 −11.271 0,09 −0,198 0,84 −1.021 0,31
rs9332214 96743108 10 CYP2C9 8.34 × 10−12 −3.442 0,72 0,03 11.271 0,09 −0,198 0,84 1.021 0,31
rs17790434 30520856 16 VKORC1 9.21 × 10−11 1.758 1.528 0,002 1.285 0,42 0,592 0,68 0,523 0,54
rs4889490 30823047 16 VKORC1 2.33 × 10−63 −3.802 −0,798 0,001 −1.950 0,08 −1.644 0,04 −1.780 0,005
Table 2. Statistically significant polymorphisms associated with maintenance dose. Description of the 
p-values and beta-values from Teichert et al.6 (P-LITER and BETA-LITER) and from our analysis for weekly 
maintenance dose (P-DOSE and BETA-DOSE), risk of recurrent stroke (P-STROKE and BETA-STROKE), 
risk of ICH (P-ICH and BETA-ICH) and from our combined analysis for ICH events and recurrent strokes 
(P-COMB and BETA-COMB). Bold numbers indicate statistically significant p-values.
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A p-value of <0.001 was considered statistically significant after correcting for the 49 polymorphisms evalu-
ated (Bonferroni test).
We also evaluated which SNPs were in linkage disequilibrium (R2 > 0.8). For the SNPs significantly associated 
with ICH events, rs7197475, rs4889490 and rs10871454 were independents. For the SNPs significantly associated 
with stroke recurrence, rs8046001, rs741810 and rs4086116 were independents and for acenocoumarol mainte-
nance dose analysis: rs17790434, rs10871454, rs8046001, rs11642466 and rs9332169 were independents.
Moreover, we have generated weighted polygenic risk scores (GRS) based on the independent polymorphisms 
(R2 < 0.8) from the Teichert et al. GWAs6 and analysed it for association with acenocoumarol maintenance 
dose, ischemic stroke recurrence and ICH events. Each value was obtained as described in the Supplemental 
Information and in Cullell N et al.28, for weighted GRS.
Survival analysis. We used the Survival package29 in R (Version 3.5.1) to perform survival analysis using 
Cox regression curves. We included age as a covariate in the Cox regression analysis.
Data availability
The data generated from this study will be made available upon request to the corresponding author.
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